Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | GAK | O14976 | 3/20 | 0.37 |
| ▸ | STK16 | O75716 | 3/20 | 0.37 |
| ▸ | BMP2K | Q9NSY1 | 3/20 | 0.37 |
| ▸ | CDKL2 | Q92772 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208005 | 0.93 | CHEK1 (0.42) | MAP4K4CHEK1AAK1PRKD1DHODH | |
| SCHEMBL3204573 | 0.92 | CHEK1 (0.47) | MAP4K4CHEK1AAK1DHODHJAK2 | |
| SCHEMBL3194725 | 0.88 | CARM1 (0.42) | MAP4K4CHEK1AAK1DHODHJAK2 | |
| SCHEMBL3207861 | 0.84 | MTOR (0.34) | CHEK1PRKD1JAK2JAK1TYK2 | |
| SCHEMBL3835840 | 0.82 | CHEK1 (0.42) | CHEK1PRKD1DHODHJAK1PARP1 | |
| SCHEMBL3204638 | 0.81 | PDGFRB (0.41) | AAK1GAKSTK16BMP2KCDKL2 | |
| SCHEMBL3212920 | 0.81 | RET (0.44) | MAP4K4JAK2PARP1CD274DYRK1A | |
| SCHEMBL3829147 | 0.80 | CHEK1 (0.47) | CHEK1PARP1 | |
| SCHEMBL3205994 | 0.80 | PARP1 (0.43) | CHEK1AAK1DHODHPARP1 | |
| SCHEMBL9884417 | 0.80 | FGFR2 (0.44) | CHEK1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119703-B1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | MAP4K4 444/4885CHEK1 1832/4885AAK1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.